Deciphera Pharmaceuticals, Inc. (DCPH)
(Delayed Data from NSDQ)
$23.59 USD
+0.67 (2.92%)
Updated May 3, 2019 04:00 PM ET
After-Market: $23.47 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[DCPH]
Reports for Purchase
Showing records 1 - 20 ( 99 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
All Is GIST Fine, While Waiting For "Vim" US and EU Filings For TGCT; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for DCPH 112123
Provider: Stock Traders Daily
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Investors Feel Positive E"MOTION" Towards Vimseltinib and Qinlock
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A